title: Involvement of gangliosides in glucosamine-induced proliferation decrease of retinal pericytes.
abstract: The hexosamine pathway (HP) is a biochemical hypothesis recently proposed explaining cellular alterations occurring during diabetic microvascular complications. Diabetic retinopathy is a common microvascular complication of diabetes, and it is known that cell proliferation is severely affected during the development of the disease. Particularly, early stages are characterized by death of the retinal microvascular cells, pericytes. Gangliosides have often been described to regulate cell growth; however, very few studies focused on the potential role of gangliosides in diabetic microvascular alterations. The aim of this article was to investigate the effect of the HP activation on pericyte proliferation and determine the potential implication of gangliosides in this process. Results indicate first that HP activation, mimicked by glucosamine treatment, decreased pericyte proliferation. Second, glucosamine treatment induced a modification of gangliosides pattern, particularly GM1 and GD3 were significantly increased. Next, results showed that exogenous addition of a-series gangliosides (GM3, GM2, GM1, GD1a) and b-series ganglioside (GD3) caused a decrease of pericyte proliferation, whereas nonsialylated precursors glucosylceramide and lactosylceramide were without effect. Furthermore, when ganglioside biosynthesis was blocked using PPMP, a glucosylceramide synthase inhibitor, the effects of glucosamine on pericyte proliferation were partially reversed. Our results suggest that in retinal pericytes, gangliosides and particularly GM1 and GD3 that are increased in response to glucosamine, are involved in the antiproliferative effect of glucosamine. These observations also underlie the potential involvement of gangliosides in a pathological context, such as diabetic microvascular complications.
authors.affiliation: Diabetic Microangiopathy Research Unit, Merck Santé-INSERM UMR 585, INSA-Lyon, Louis Pasteur Bldg, 69621 Villeurbanne Cedex, France.
authors.forename: Elodie
authors.initials: E
authors.lastname: Masson
authors.forename: Nicolas
authors.initials: N
authors.lastname: Wiernsperger
authors.forename: Michel
authors.initials: M
authors.lastname: Lagarde
authors.forename: Samer
authors.initials: S
authors.lastname: El Bawab
mesh_terms: D000818:Animals; D002417:Cattle; D049109:Cell Proliferation / Q000187:drug effects*; D005677:G(M1) Ganglioside / Q000378:metabolism / Q000494:pharmacology; D005732:Gangliosides / Q000037:antagonists & inhibitors / Q000378:metabolism* / Q000494:pharmacology; D005944:Glucosamine / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D008614:Meperidine / Q000031:analogs & derivatives / Q000494:pharmacology; D020286:Pericytes / Q000187:drug effects / Q000378:metabolism*; D012160:Retina / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*
chemical_list: D005732:Gangliosides; C026733:4-propionyloxy-4-phenyl-N-methylpiperidine; D005677:G(M1) Ganglioside; C026226:ganglioside, GD3; D008614:Meperidine; D005944:Glucosamine